# NCI National Clinical Trials Network - Lead Academic Participant Sites

> **NIH NIH UG1** · UNIVERSITY OF COLORADO DENVER · 2024 · $618,036

## Abstract

Project Summary
This grant will provide infrastructure support to the University of Colorado Consortium Cancer Center
and its clinical care partner UCHealth to continue to support the specific aims of the grant:
 To lead and participate in scientifically important and clinically relevant NCTN clinical trials.
 To make these trials available to the greatest proportion of the cancer population of Colorado and
Wyoming.
 To rapidly activate, accrue, caringly provide patient coordination, and accurately report research
 related data in a timely way to the NCTN components responsible for conducting these trials.
 To foster and develop young investigators in the NCTN process.
Specific support is requested for the administrative, regulatory, clinical coordination, and data
management needs to conduct clinical trials of the NCTN safely and efficiently on behalf of the cancer
patients in Colorado and our wider catchment area. In addition, we will support enhanced monitoring
and auditing to ensure patient safety and proper conduct of the trials at all our sites of clinical care.
Quality assessment and improvement are a central features of our NCTN program.
We take seriously the mandate to participate in the development of new concepts, the contribution of
our laboratory scientists in these translational projects, and the fostering of new junior investigators to
further the clinical impact of therapeutic trials in the NCTN. Dialog and communication are key. Within
our institution, we have created a superb forum for our investigators across the entire system (the LAPS
Executive Committee) that represents all modalities and disease-oriented groups to prioritize and
commit to new trials, to monitor accrual and any other issues related to the conduct of these trials
across our system. We support travel for investigators, staff, and scientists to participate in the NCTN
meetings and committees.
A new initiative will be supported with this grant. Many of the new trials are multi-oncologic, and/or
require molecular characterization of the patient's tumor to match the patient to appropriate treatment
protocols. Our institution already has a “T3” CRA team to handle multi-oncologic “basket” trials, and we
have a fully functional Molecular Tumor Board. In separate efforts, we are developing patient-specific
molecular databases that will obtain both internal and external molecular tumor data, and will be
searchable. A navigator position to regularly review these databases, the molecularly-driven clinical
trials, and guide patients and clinicians to match the patients to the suitable trials may improve our
accrual to these trials.

## Key facts

- **NIH application ID:** 10795880
- **Project number:** 5UG1CA233324-06
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **Principal Investigator:** ANTHONY D ELIAS
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $618,036
- **Award type:** 5
- **Project period:** 2019-03-29 → 2026-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10795880

## Citation

> US National Institutes of Health, RePORTER application 10795880, NCI National Clinical Trials Network - Lead Academic Participant Sites (5UG1CA233324-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10795880. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*